Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo OTC Brand Journey Detours Into Management, Operating Problems

This article was originally published in The Tan Sheet

Executive Summary

The firm's report of problems in its European branded product business during its earnings briefing prompted a sharp dip in its share price, closing down more than 10% at $130.40, and left analysts looking for its private label OTC business to continue as its growth driver.


Related Content

Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts